title: Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study.
abstract: BACKGROUND
  The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism in the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population.
  
  
  METHODS
  This case- control study included 100 histopathologically confirmed NSCLC (ADC) patients and 100 healthy controls. EGF (A61G) was genotyped by AS-PCR to elucidate putative associations with clinical outcomes. The association of the polymorphism with the survival of NSCLC patients was estimated by Kaplan-Meier curves.
  
  
  RESULTS
  It was found that EGF 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of NSCLC (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p=0.005) and homozygous GG (p=0.009)]. Patients homozygous for the G allele exhibited a significantly poor overall survival. The median survival time for patients with EGF 61 AA, AG, and GG genotypes was 10.5, 7.4, and 7.1 months (p=0.02), respectively. NSCLC (ADC) patients with GG + AG exhibited 7.3 months median survival compared to the AA genotype (p=0.009).
  
  
  CONCLUSIONS
  The present study revealed that the EGF A61G genotype may be a novel independent prognostic marker to identify patients at higher risk of occurrence and an unfavourable clinical outcome.
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi, India E-mail : biochempublications@gmail.com.
authors.forename: Mirza
authors.initials: M
authors.lastname: Masroor
authors.forename: Jain
authors.initials: J
authors.lastname: Amit
authors.forename: Jamsheed
authors.initials: J
authors.lastname: Javid
authors.forename: Rashid
authors.initials: R
authors.lastname: Mir
authors.forename: Y
authors.initials: Y
authors.lastname: Prasant
authors.forename: A
authors.initials: A
authors.lastname: Imtiyaz
authors.forename: Z
authors.initials: Z
authors.lastname: Mariyam
authors.forename: Anant
authors.initials: A
authors.lastname: Mohan
authors.forename: P C
authors.initials: PC
authors.lastname: Ray
authors.forename: Alpana
authors.initials: A
authors.lastname: Saxena
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality; D016022:Case-Control Studies; D004815:Epidermal Growth Factor / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007194:India; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011379:Prognosis; D012306:Risk
chemical_list: D014408:Biomarkers, Tumor; D004815:Epidermal Growth Factor